54287-92-2

Basic information

• Product Name: Carbamic acid, N-4-pyridinyl-, ethyl ester
• Synonyms: Carbamic acid, N-4-pyridinyl-, ethyl ester;ethyl 2-aminopyridin-4-ylcarbamate;4-(Ethoxycarbonylamino)pyridine;4-Pyridinecarbamic acid ethyl ester;Ethyl (4-pyridinyl)carbamate;Ethyl 4-pyridinecarbamate;Ethyl 4-pyridylcarbamate;Ethyl pyridin-4-ylcarbamate
• CAS NO: 54287-92-2
• Molecular Formula: C8H10N2O2
• Molecular Weight: 166
• Mol File: 54287-92-2.mol
• Article Data: 13

Chemical Properties

• Melting Point: 130-131℃
• Boiling Point: 229℃
• Flash Point: 92℃
• Appearance: /
• Density: 1.198
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Carbamic acid, N-4-pyridinyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, N-4-pyridinyl-, ethyl ester(54287-92-2)
• EPA Substance Registry System: Carbamic acid, N-4-pyridinyl-, ethyl ester(54287-92-2)

Safety Data

• Hazardous Substances Data: 54287-92-2(Hazardous Substances Data)

Usage

General Description

Carbamic acid, N-4-pyridinyl-, ethyl ester is a chemical compound with the molecular formula C8H10N2O2. It is an ester of carbamic acid and is derived from ethyl alcohol and 4-pyridinylamine. It is used as a reagent in the synthesis of pharmaceutical compounds and in the production of pesticides and herbicides. It is a colorless liquid with a faint odor, and it is soluble in water and organic solvents. It is important to handle this chemical with care as it can be hazardous if not properly managed and disposed of.

Upstream product

• 504-24-5 4-aminopyridine 
• 541-41-3 chloroformic acid ethyl ester 
• 3278-35-1 S-(ethoxycarbonyl) O-ethyl dithiocarbonate 
• 1336-21-6 ammonium hydroxide 

Relevant articles and documents

A scalable and facile process for the preparation of N-(pyridin-4-yl) piperazine-1-carboxamide hydrochloride

A scalable and facile synthetic process for N-(pyridin-4-yl)piperazine-1-carboxamide hydrochloride, a novel Rho kinase inhibitor with an unsymmetrical urea structure currently under investigation for the treatment of central nervous system disorders, was established. After optimisation of the reaction conditions, N-(pyridin-4-yl)piperazine-1-carboxamide hydrochloride was synthesised from 4-aminopyridine and N,N'-carbonyldiimidazole through acylation, deprotection and salt formation. This new procedure affords the product in 53% overall yield with high purity and it can be easily scaled up for production.

Design, Synthesis, and Biological Evaluations of Several Y-26732 Analogues

A series of pyridine Rho kinase inhibitors were designed and synthesized utilizing the ligand-binding pocket model with Y-26732 as the lead compound. These compounds were evaluated on cell lines for their biological activities.

DOSAGE OF 4-AMINOPYRIDINE DERIVATIVES FOR TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES

The invention provides novel pyridines, pharmaceutical compositions comprising such pyridines, and the use of such compositions in treating injured mammalian nerve tissue, including but not limited to an injured spinal cord, in one embodiment, the compounds, compositions, and methods of the instant invention treat a mammalian nerve tissue injury by restoring action potential or nerve impulse conduction through a nerve tissue lesion. Significantly,in vivo application of compounds of the instant invention established, on the basis of SSEP testing, that the compounds provide longer lasting effects at lower concentrations than comparable treatment with the known agent 4-aminopyridine (4 AP).Λ''invention concerne de nouvelles pyridines, des compositions pharmaceutiques comprenant ces pyridines et l''utilisation de ces compositions dans le traitement des lésions du tissu nerveux mammifère, y compris mais non de fa?on limitative, une lésion de la moelle épinière. Dans un mode de réalisation, les composés, les compositions et les méthodes selon l''invention traitent une lésion du tissu nerveux mammifère en rétablissant le potentiel d''action ou la conduction nerveuse à travers une lésion du tissu nerveux. De manière significative, l''application in vivo de composés selon l''invention établit, sur la base d''un test de potentiel évoqué somesthésique, que les composés produisent à de faibles concentrations des effets plus durables qu''un traitement comparable à l''aide de l''agent 4-aminopyridine (4 AP) connu.